Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;329:170 (17 July), doi:10.1136/bmj.329.7458.170
| The first 150 words of the full text of this article appear below. |
EDITORKell and Kerin wrote about sentinel lymph node biopsy in breast cancer and melanoma.1 This is a staging procedure with a well established role in breast cancer, reducing the need for dissection of the axillary node. The indications and advantages for sentinel lymph node biopsy in melanoma are not confirmed, and it is certainly not the established treatment implied in the editorial.2
Sentinel node status in melanoma is indeed the best staging and prognostic indicator: patients with negative results have a better prognosis then those with positive results. However, there is no evidence from randomised clinical trials that completion lymphadenectomy (sometimes known as selective lymphadenectomy) in patients with positive sentinel node biopsies offers any survival advantage. Neither is there any adjuvant therapy that can influence the natural history and benefit patients who are sentinel node positive.3 Concern has recently been raised about the possible increased incidence of local
J Meirion Thomas, consultant surgical oncologist
sarcoma@mac.com
Matthew A Clark, consultant surgical oncologist
Royal Marsden Hospital Melanoma and Sarcoma Unit, London SW3 6JJ
Read all Rapid Responses